SOURCE: Medpace

Medpace

April 18, 2012 08:00 ET

Medpace CEO and Founder, August J. Troendle, MD, Accepts the Lifetime Achievement Award for Innovation From the Cincinnati USA Regional Chamber

CINCINNATI, OH--(Marketwire - Apr 18, 2012) - Medpace, Inc. a global full-service clinical research organization (CRO), today announced August Troendle, MD, CEO and Medpace founder, is the recipient of the Lifetime Achievement Award for Innovation from the Cincinnati USA Regional Chamber. Presented by the Cincinnati USA Regional Chamber, the Business Courier, and CincyTech, the Innovation Awards celebrate innovative companies and people in the greater Cincinnati area.

Dr. Troendle accepted the award at a reception on Tuesday, April 17. He outlined how Medpace has continued to succeed as a CRO in the increasingly competitive life sciences sector, sharing innovative techniques that have driven growth for Medpace.

The Medpace business model represents a different approach in comparison to many other CROs. Medpace offers internal expertise in the design and conduct of clinical trials -- embedding robust expertise at every stage of the program. Medpace is a true partner to the biopharmaceutical and medical device firms who need to conduct studies efficiently and effectively to win the race to market. True strategic partnering allows drug and device development programs to be conducted more quickly from beginning to end.

"I am pleased to accept this award on behalf of myself and Medpace. Medpace has created an innovative business model, but we depend upon local talent to make it work," said Dr. Troendle. "The continued support from the City of Cincinnati, the Madisonville neighborhood, and the State of Ohio are important to our success."

Medpace will complete its transition from Norwood to the Madisonville site this summer. A former brownfield industrial site has been transformed to a clean, environmentally friendly, high technology campus that will contribute to the revitalization of Madisonville and the continued development of the Red Bank corridor.

ABOUT MEDPACE
Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry's most experienced and therapeutically focused teams to execute at every level of the company's operations, providing complete and seamless drug development services.

Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.

With more than 1000 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, centralized imaging core laboratory management and reading from Imagepace, and medical device development from Medpace Medical Device.

Visit the Medpace website at www.medpace.com